Akademy Pharma

Akademy Pharma is an Italian pharmaceutical company that specializes in the development of evidence-based nutraceuticals and bio-pharmaceutical products. Founded by Vincenzo Maglione, the company serves as the innovation hub for its subsidiary, Farmaceutici Damor, which it acquired in 2018. Akademy Pharma focuses on therapeutic areas including metabolism, cardiovascular health, dermatology, and menopause, leveraging a pipeline of programs designated as the AKP series. Its flagship product, LopiGLIK, is a patented nutraceutical designed to manage cholesterol and glucose levels through a combination of berberine, red yeast rice, and Morus alba. The company maintains strong ties with academic institutions, particularly the University of Naples Federico II, to validate the clinical efficacy of its formulations.